Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
You may also be interested in...
House tries again to promote advanced technology for the return of pharmaceutical manufacturing to the US in post-COVID-19 era.
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.
“Any practices that limit the social interaction between the investigator and the firm are always good,” says FDA ORA official Rachel Harrington. Donald Ertel, of FDA’s Center for Biologics Evaluation and Research, encourages firms to “try to maintain a one-way flow through the facility” for investigator plant walkthroughs.